Overview

SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study

Status:
Terminated
Trial end date:
2014-03-27
Target enrollment:
Participant gender:
Summary
This study is an optional continuation of previous short-term adult major depressive disorder (MDD) augmentation studies. Patients may only take part in this long-term, open-label research study if they completed a previous double-blind MDD augmentation study using SPD489.
Phase:
Phase 3
Details
Lead Sponsor:
Shire
Treatments:
Antidepressive Agents
Lisdexamfetamine Dimesylate